Beone Medicines Ltd. (BEIGF) Stock Price & Analysis
Beone Medicines Ltd. (BEIGF) rose 5.54% to USD 23.75 as of June 9, 2026 at 23:51 UTC, according to Nexqual real-time market data.
BEIGF last closed at USD 22.5; the session ranged USD 23.75–23.75 on volume of 100 shares. Market capitalization is $32.03B, with a 52-week range of USD 15.95–25.3 (PNK). Source: Nexqual, June 9, 2026 at 23:51 UTC.
Key Statistics (as of June 9, 2026 at 23:51 UTC)
| Price | USD 23.75 |
|---|---|
| Change | ▲ 5.54% (up) |
| Previous Close | USD 22.5 |
| Open | USD 23.75 |
| Day Range | USD 23.75 – 23.75 |
| 52-Week Range | USD 15.95 – 25.3 |
| Volume | 100 shares |
| Market Cap | $32.03B |
| Exchange | PNK |
Technical Analysis (BEIGF)
Nexqual's technical model rates BEIGF "SELL" based on 3 bullish and 5 bearish signals across 124 daily candles, as of June 9, 2026 at 23:51 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 0 (oversold) |
| vs SMA50 | Above (USD 22.67) |
| MACD | -0.1 (negative) |
Analyst Ratings (BEIGF)
Wall Street analysts rate BEIGF "None", per Nexqual as of June 9, 2026 at 23:51 UTC.
| Consensus Rating | None |
|---|
Earnings (BEIGF)
| Next Earnings Date | 2026-08-05 |
|---|---|
| Revenue Estimate | $1.59B |
Source: Nexqual, June 9, 2026 at 23:51 UTC.
Financials & Fundamentals (BEIGF)
| Total Revenue | $5.74B |
|---|---|
| Revenue Growth (YoY) | +35.50% |
| Gross Margin | +88.31% |
| Operating Margin | +16.51% |
| Profit Margin | +8.94% |
| ROE | +12.42% |
| Debt / Equity | 24.14 |
| Current Ratio | 3.64 |
| Total Cash | $4.79B |
| Total Debt | $1.15B |
| Free Cash Flow | $917.30M |
Source: Nexqual, June 9, 2026 at 23:51 UTC.
Financial Health Score (BEIGF)
Nexqual rates Beone Medicines Ltd.'s overall financial health "Strong" across five dimensions, as of June 9, 2026 at 23:51 UTC.
| Growth | Strong — Revenue +40% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 88%, operating 17% |
| Balance Sheet | Strong — $4.79B cash vs $1.15B debt, net cash position |
| Cash Flow | Strong — FCF $917M, 17% margin |
| Efficiency | Mixed — ROE 12%, ROA 6.0% |
Ownership (BEIGF)
| Insider Ownership | +13.87% |
|---|---|
| Institutional Ownership | +28.09% |
| Shares Outstanding | 1.23B |
| Float | 1.01B |
Source: Nexqual, June 9, 2026 at 23:51 UTC.
Leadership (BEIGF)
Beone Medicines Ltd. is led by John V. Oyler (age 57), Co-Founder, Executive Chairman & CEO, per Nexqual as of June 9, 2026 at 23:51 UTC.
| Co-Founder, Executive Chairman & CEO | John V. Oyler (age 57) |
|---|---|
| President and Global Head of Research & Development | Wang Lai (age 47) |
| Co-Chairman of Scientific Advisory Board, Non-Executive Director & Co-Founder | Xiaodong Wang (age 62) |
| Chief Financial Officer | Aaron Rosenberg (age 48) |
| Chief Technology Officer | Marcello Damiani (age 55) |
Major Backers & Investors (BEIGF)
Notable institutional backers of Beone Medicines Ltd. include T. Rowe Price, NEW PERSPECTIVE FUND, Fidelity, according to Nexqual as of June 9, 2026 at 23:51 UTC.
Active Investors
| Investor | Stake |
|---|---|
| T. Rowe Price | 0.4% |
| NEW PERSPECTIVE FUND | 0.2% |
| Fidelity | 0.11% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 1.68% |
| BlackRock | 1.24% |
Source: Nexqual, June 9, 2026 at 23:51 UTC.
From Beone Medicines Ltd.'s Latest SEC 10-K Filing (filed 2026-02-26)
Key Strengths & Strategy (as disclosed to the SEC)
- BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally.
- The company's commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; SYLVANT for the treatment of adult patients with multicentric castleman disease; BAITUOWEI for patients with BC in premenopausal and perimenopausal women, and cancer; and PARTRUVIX for the treatment of various solid tumors.
- The company has agreements Amgen, BMS, Bio-Thera, EUSA Pharma, Luye Pharmaceutical, and Novartis.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ARGNF | ARGENX SE | USD 803.19 | ▼ 3.81% |
| BNCZF | BANCO BPM SPA | USD 15.51 | ▼ 2.76% |
| DNBBY | DNB ASA | USD 29.93 | ▼ 0.07% |
| BFSAF | BEFESA SA | USD 40.7 | ▲ 1.75% |
| APPTF | AUTOMOTIVE PPTYS REAL ESTATE IN | USD 8.6 | ▼ 3.26% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 9, 2026 at 23:51 UTC. This page is informational and not investment advice.